Singla Smit, Hochwald Steven N, Kuvshinoff Boris
Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA.
Biomed Res Int. 2014;2014:230174. doi: 10.1155/2014/230174. Epub 2014 Apr 29.
The liver is a common site for both primary and secondary malignancy. Hepatic resection and transplantation are the two treatment modalities that have been shown to achieve complete cure, but only 10 to 20% of patients are candidates for these treatments. For the remaining patients, tumor ablation has emerged as the most promising alternative modality. In addition to providing local control and improving survival outcomes, tumor ablation also helps to down stage patients for potential curative treatments, both alone as well as in combination with other treatments. While tumor ablation can be achieved in multiple ways, the introduction of newer ablative techniques has shifted the focus from palliation to potentially curative treatment. Because the long-term safety and survival benefits are not substantive at present, it is important that we strive to evaluate the results from these studies using appropriate comparative outcome methodologies.
肝脏是原发性和继发性恶性肿瘤的常见发生部位。肝切除术和肝移植是已被证明可实现完全治愈的两种治疗方式，但只有10%至20%的患者适合这些治疗。对于其余患者，肿瘤消融已成为最有前景的替代治疗方式。除了提供局部控制和改善生存结果外，肿瘤消融还有助于降低患者分期以便进行潜在的根治性治疗，无论是单独使用还是与其他治疗联合使用。虽然肿瘤消融可以通过多种方式实现，但更新的消融技术的引入已将重点从姑息治疗转向潜在的根治性治疗。由于目前长期安全性和生存益处尚不显著，因此我们必须努力使用适当的比较结果方法来评估这些研究的结果。
